GLP-1 Care Through Perimenopause and Menopause

The midlife metabolic shift is real

Many women feel that their body changed almost overnight in their forties, and the science backs that up. Across the menopause transition, body composition shifts toward more fat and less lean mass, and weight tends to creep up in a way that pre-menopausal habits no longer control². Falling and fluctuating estrogen is part of why fat redistributes toward the abdomen, raising metabolic risk even when the number on the scale moves only modestly⁴. The same transition thins hair on its own timetable, which is why midlife shedding that starts after a GLP-1 is so easily misattributed — telling the two apart changes what you do about it.

Where GLP-1 medicines fit

GLP-1 receptor agonists act on appetite and insulin response rather than on estrogen, so they address the metabolic side of the transition, not the hormonal one directly. In the STEP 1 obesity trial, once-weekly semaglutide produced a mean weight reduction of about 15%, with a substantial share of participants being midlife women³. For many women, the most sensible framing is GLP-1 care as one tool alongside — not instead of — a conversation about menopausal hormone therapy, sleep, strength training and cardiovascular risk¹. That last point deserves its own scrutiny: the landmark trial behind the "GLP-1s reduce cardiovascular risk" claim enrolled a population that skewed heavily male, which our guide to heart disease risk in women unpacks — worth reading given that cardiovascular risk itself rises sharply once estrogen's protective effect fades after menopause.

Choosing a provider in this stage of life

Because perimenopause layers hormonal symptoms on top of metabolic ones, oversight and labs matter more here, not less. A provider that checks thyroid and metabolic markers, understands where you are in the transition, and can coordinate with the clinician managing any hormone therapy is worth more than the cheapest sticker price. That is why our ranking weights clinical oversight and hormonal suitability heavily — see the full Luna Fit Score methodology, and our reviews of hormone- and longevity-aware programs. If you want the provider question answered directly rather than the evidence behind it, we score every program on those midlife-specific factors on our menopause ranking, and the overall women's ranking ranks the same roster on all six factors at once.

The cautions that matter

One midlife-specific consequence deserves naming before you start: fast weight loss in this window costs lean mass at an age when bone and muscle are already under pressure, which our guide to muscle loss on a GLP-1 in midlife covers along with what to ask a program about it. Bone follows a similar pattern — a randomized trial in adults at elevated fracture risk found measurably lower bone density in the semaglutide group at one year, which our guide to GLP-1 and bone density covers in full, and it matters more here than at other ages because postmenopausal bone loss is already the steepest of any life stage. Postmenopausal breast cancer risk is another place this transition changes the calculus, covered in our guide to GLP-1 and breast cancer history. If you would rather read the programs than the evidence, every one we score is written up individually in our provider reviews.

GLP-1 medicines are not appropriate during pregnancy, which still matters in perimenopause because ovulation can be unpredictable rather than absent. They can also affect the absorption of oral medications. As always, this is educational information, not medical advice — decisions in this stage of life are best made with a clinician who can see your whole picture¹.